These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New treatment may eradicate virulent lymphoma. A single course of infections kills cancers, with minimal side-effects; positive responses immediate. Health News; 2005 May; 11(5):6-8. PubMed ID: 15887314 [No Abstract] [Full Text] [Related]
3. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]. de Nully Brown P; Jurlander J; Lindén O; Hansen M Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425 [TBL] [Abstract][Full Text] [Related]
4. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Buchegger F; Press OW; Delaloye AB; Ketterer N Oncologist; 2008 Jun; 13(6):657-67. PubMed ID: 18586921 [TBL] [Abstract][Full Text] [Related]
5. [Targeted destruction of lymphomas with the aid of radioimmunotherapy. Tumor antibodies isotope taxi]. MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373026 [No Abstract] [Full Text] [Related]
6. Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure? Chatal JF; Kraeber-Bodéré F; Barbet J Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1236-9. PubMed ID: 18330570 [No Abstract] [Full Text] [Related]
7. Radioimmunotherapy in follicular lymphoma: an update. Mace JR Clin Adv Hematol Oncol; 2012 Jun; 10(6):394-6. PubMed ID: 22895242 [No Abstract] [Full Text] [Related]
8. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857 [TBL] [Abstract][Full Text] [Related]
9. [Therapy of follicular lymphoma]. Buske C; Unterhalt M; Hiddeman W Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Dillman RO Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy--hot new treatment for lymphoma. Connors JM N Engl J Med; 2005 Feb; 352(5):496-8. PubMed ID: 15689589 [No Abstract] [Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
13. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Rose AC; Shenoy PJ; Garrett G; Seward M; Kucuk RA; Doksansky H; Nastoupil LJ; Flowers CR Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):393-9. PubMed ID: 23158095 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy in follicular lymphoma. Illidge T; Morschhauser F Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624 [TBL] [Abstract][Full Text] [Related]
15. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
16. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine (131)I tositumomab). Cooney J; Stiff P; Kaminski M Bone Marrow Transplant; 2002 Mar; 29(6):523-5. PubMed ID: 11960274 [TBL] [Abstract][Full Text] [Related]
17. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. Scholz CW; Pinto A; Linkesch W; Lindén O; Viardot A; Keller U; Hess G; Lastoria S; Lerch K; Frigeri F; Arcamone M; Stroux A; Frericks B; Pott C; Pezzutto A J Clin Oncol; 2013 Jan; 31(3):308-13. PubMed ID: 23233718 [TBL] [Abstract][Full Text] [Related]
18. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma. Plastaras JP; Glatstein E; Schuster SJ Oncologist; 2008 Jun; 13(6):655-6. PubMed ID: 18586920 [No Abstract] [Full Text] [Related]
20. The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics? Leung N; Witzig TE Leuk Lymphoma; 2013 Dec; 54(12):2586-7. PubMed ID: 23734658 [No Abstract] [Full Text] [Related] [Next] [New Search]